Tempus

Our single platform offers a comprehensive portfolio and a vast multimodal database, helping to generate more personalized patient care. As your trusted partner across the patient journey, Tempus is changing the way precision oncology care is delivered through trusted science,…

We’re excited to announce the expansion of our care pathway intelligence platform, Tempus Next, into breast cancer. The platform will support five different biomarker testing gaps specific to breast cancer with the goal of helping physicians deliver guideline-directed medical…

At our #AACR25 Exhibitor Spotlight Theater, Ryan Fukushima, Chief Operating Officer at Tempus, and Robert Shoemaker, Ph.D., Senior Vice President of Research at Erasca, Inc., spoke about the transformative power of artificial intelligence in oncology research and drug…

We will report financial results for the second quarter of 2025 on Friday, August 8, 2025, at 8:00 a.m. ET. Our quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio…

🚨ICYMI: Last week we announced the expansion and extension of our strategic collaboration with @TempusAI. Personalis and Tempus will now work to bring to market the NeXT Personal® ultrasensitive, tumor-informed minimal residual disease (MRD) test to detect cancer recurrence in…

Join us for an upcoming webinar on July 29. Ezra Cohen, MD, Molly Porter, MSN, FNP-BC and Jay Carlson, DO, MS will be exploring how providers can navigate the complexities of breast cancer treatment by integrating the latest clinical guidelines, with insights from AI-driven care…

We are excited to share that we have received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for our Tempus ECG-Low EF software, which uses AI to identify patients who may have a low left ventricular ejection fraction (LVEF).  This is our second FDA approved…

A new Tempus study published in @JCOOP_ASCO illustrates how comprehensive genomic profiling enables timely delivery of matched targeted therapies and helps patients access emerging treatments—without the need for additional biopsies or delays. Read the full study:…

We offer a comprehensive portfolio of fixed PDO panels to support your preclinical oncology R&D. Assess the efficacy of your drug candidates across a variety of therapeutic modalities—including small molecules, monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), cell…

#NowHiring: We're looking for a Senior Scientist, Applied Machine Learning and Generative AI, Pharma R&D to execute analytical projects and capability builds to advance the Tempus drug R&D platform. Apply and learn more here: bit.ly/4eyQjDI

A study recently published in @ClinicalLung analyzed real-world data to better understand outcomes among patients with advanced #NSCLC receiving first-line immunotherapy. Results showed that patients’ median overall survival varied when treated with immune checkpoint inhibitors…

Clinical laboratories are using artificial intelligence (AI), machine learning, and advanced diagnostics to power precision medicine and improve patient outcomes. Hear from Dr. Kate Sasser, CSO of @TempusAI, on how data and technology are transforming #ThePowerofKnowing.

Our suite of oncology solutions uses AI to streamline complex clinical & molecular data, providing you with on-demand access to patient insights through tools like the Tempus One clinical assistant. Our AI-enabled technologies provide solutions that reduce workflow burden &…

Our #ASCO25 Industry Expert Theater presentation dove into the cutting-edge AI-enabled technologies that are embedded across Tempus’ platform to enhance insights, streamline care and drive innovation. Watch a recording of the presentation here: tempus.co/4kSIrix

Join us for an upcoming webinar on Monday, July 14. Hear from Arun Krishna and Ahmed ElNawawi, alongside Ryan Fukushima, as they unveil innovative strategies to optimize market understanding of therapy trends and adherence to guideline driven care in the dynamic field of…

Organoids are emerging as powerful preclinical models in oncology R&D, with the potential to improve prediction and reduce translational risk. Our white paper offers insights on the scientific landscape, adoption barriers, and how pharma companies are using organoids to advance…

Exciting to see Tempus’ AI-driven clinical solutions for cardiovascular disease featured in @NYTmag's recent piece showcasing AI’s ability to recognize patterns within the human body. These solutions play a critical role in enabling earlier detection of cardiovascular disease.…

We're on-site at #AANP25 San Diego, California. Stop by Booth #536 to meet with the our team and learn more about Tempus Notetaker, our AI tool built for psychiatry that identifies pharmacogenomic (#PGx) care gaps and provides real-time PGx insights, with hyperlinked evidence…

We’re proud to celebrate and support the LGBTQ+ community. Our Pride Employee Resource Group has planned a month of meaningful events, from letter writing to queer youth and elders, bracelet making to educate about the different pride flags, to yoga sessions and a book club…

We are proud to announce a collaboration with @ARC_Neuro at Northwestern University Feinberg School of Medicine to harness AI for rapid discovery and innovation in Alzheimer’s disease research. Using Lens, the Center and Tempus teams will work together to uncover genomic patterns…